When Disraeli supposedly said “The only two certainties in life are death and taxes” he could not have imagined that little over a century later, such rock-solid logic could be under threat. If a team of Croatian scientists, led by Professor Miroslav Radman, are correct, death need be no certainty. DrugBaron was fortunate to spend several days with Prof Radman and his team earlier this year, and hear about his research into proteome instability, and the insights that has given him into the mechanism of aging. Most intriguingly, these insights have the potential to underpin a whole pipeline of novel therapeutics for a wide range of degenerative diseases, and perhaps, ultimately, for aging itself.
Search Our Blog
- Twitter API is Currently Down.
Above the Crowd
Both Sides of the Table
First Round Capital
Master of 500 Hats
Since 2007, Index Ventures has been the largest shareholder in a rising star of pharma companies, ProFibrix - a visionary company whose lead product aims to save lives and speed recovery for patients undergoing bleeding during surgery and after trauma.
Today, our belief in ProFibrix - and particularly in founder Jaap Koopman, PhD - has been justified with the news of their acquisition by The Medicines Company.
Comparing the founding of two virtual drug development companies, Funxional Therapeutics in 2006 and XO1 earlier in 2013 proves at least one thing: in just seven years it has become dramatically easier and quicker to create a virtual drug development company. Today it is even possible to take virtual to its logical extreme: a zero person biotech company.
In 2010, in my blog, DrugBaron, I declared the death of incremental innovation and wrote the obituary. It didn’t seem a very bold statement at the time - increasing payor pressure was beginning to bite, and it seemed obvious that the entrenched practice of paying a premium for small (often imperceptible) improvements was passing...
Index Ventures is leading a €2.5m Series A investment alongside Angel investors in Paris-based Rad, a discovery platform for cool fashion, art and design products. Here, Martin Mignot who is joining the Board, explains why we are excited to be working with them…
A tidal wave of technological disruption is rolling through the financial services sector - and not before time, says Jan Hammer, partner at Index Ventures.
Why we decided to back Capitaine Train with €500k of seed capital last year, and to keep supporting them today with a €1.1m contribution to their Series A.
Index Ventures recently completed an $11M Series A investment in XO1, an asset-centric company established with the sole objective of developing the monoclonal antibody Ichorcumab under license from Cambridge University.
If ever there was a case of a demo sealing the deal, then this was it. From the moment we saw Anki Drive cars racing around their track, our minds were made up. Those hundreds of hours I’d spent as a kid, battling electric-powered cars against my friends came flooding back. The Anki team -- who are set to ignite an explosive new category of entertainment experiences, paving the way for a consumer robotics revolution -- had killed it. We were hooked. The deal was all but done.
More and more biotech entrepreneurs and investors, alike, are realizing the considerable risks associated with simultaneous development of multiple assets and instead opting for a more streamlined approach that has come to be known as “asset-centricity.”